Bosutinib For Autosomal Dominant Polycystic Kidney Disease
Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
This purpose of this study is to determine if bosutinib reduces the rate of kidney
enlargement in subjects with autosomal dominant polycystic kidney disease (ADPKD) entering
the study with a total kidney volume greater than or equal to 750 cc and eGFR greater than or
equal to 60 mL/min/1.73m2.